Neuromuscular toxicities of paclitaxel 210 mg m-2 by 3-hour infusion

British Journal of Cancer

Volumn 77, Issue 10, 1998, Pages 1686-1688

  Kunitoh, H ^a   Saijo, N ^b   Furuse, K ^c   Noda, K ^d   Ogawa, M ^e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Arthralgia; Myalgia; Paclitaxel; Peripheral neuropathy; Pharmacokinetics; Risk factor

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROMUSCULAR DISEASE; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 0031981324     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.278     Document Type: Article

References (11)

1. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC and Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy, clinical and electrophysiological studies. Ann Neurol 35: 304-311
2. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van Der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B and Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
3. Gianni L (1995) Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6: 861-863
4. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G and Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190
5. Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101-130
6. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y and Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606
7. Poxima TJ, Vermorken JB, Liefting AJM, Pinedo HM and Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494
8. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C and Spriggs D (1994) Phase 1 trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241-248
9. Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, Kunikane H, Arioka H, Karato A, Omatsu H, Nakashima H and Saijo N (1994) Phase 1 and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res 85: 1057-1062
10. Tamura T, Sasaki Y, Nishiwaki Y and Saijo N (1995) Phase 1 study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86: 1203-1209
11. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB and Dutcher JP (1987) Phase 1 trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232-1239